Advaxis Inc. (NASDAQ:ADXS)’s share price traded up 8.2% during trading on Monday . The company traded as high as $11.38 and last traded at $11.11, with a volume of 711,187 shares. The stock had previously closed at $10.27.
A number of equities research analysts have recently issued reports on ADXS shares. Jefferies Group reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Advaxis in a research note on Friday. HC Wainwright reissued a “buy” rating and set a $23.00 price target on shares of Advaxis in a research report on Friday, August 5th. Barclays PLC increased their price target on shares of Advaxis from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, August 3rd. Finally, FBR & Co reissued an “outperform” rating and set a $34.00 price target on shares of Advaxis in a research report on Thursday, July 7th. Five investment analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $24.60.
The company’s market cap is $434.30 million. The stock’s 50 day moving average price is $11.97 and its 200 day moving average price is $9.24.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/12/advaxis-inc-adxs-trading-8-2-higher.html
In other news, Director Richard J. Berman sold 18,000 shares of the business’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $15.21, for a total transaction of $273,780.00. Following the completion of the sale, the director now directly owns 66,430 shares of the company’s stock, valued at $1,010,400.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Sidransky sold 22,808 shares of the business’s stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $15.01, for a total transaction of $342,348.08. Following the sale, the director now directly owns 91,759 shares of the company’s stock, valued at $1,377,302.59. The disclosure for this sale can be found here. Insiders own 4.56% of the company’s stock.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.
Receive News & Ratings for Advaxis Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Advaxis Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.